Jens Juul Holst

speaker

287 appearances 1 recordings 1 series first heard May 2026 last heard 4 May

Jens Juul Holst’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in May 2026 with 1.

newest first · ▶ plays the moment

Discovery · The Life Scientific: Jens Juul Holst · 4 May 2026 podcast

And they were, of course, designated glucagon-like peptides one and glucagon-like peptides two.

And that's the GLP-1 and GLP-2, yeah.

So that opened the field, I must say.

So first of all, we pulled out the natural peptide from tissues and found out that it stimulated insulin secretion directly.

And the question was then, is this really interesting?

And the prediction was, no, no, it's not interesting because people with type 2 diabetes, you know, they have lousy beta cells.

They don't react to anything.

They don't even react to glucose.

And it didn't react to this first incretin hormone, GIP.

It didn't react to those either.

So the probability that this would make any change was very, very small.

But again, we had put it on our pancreas and found out.

I had a pancreas in the laboratory, you know, a living pancreas.

Isolated living as a tool.

It was really fun.

And it also inhibited glucagon secretion.

Now, there's a problem in people with diabetes that they have too much glucagon at the wrong times.

And here we had something that could inhibit glucagon secretion.

And this was news.

So now we had two features of this hormone that could be interesting in diabetes.

Showing 121–140 of 287 · page 7 of 15